Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review

Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review

Background and objective It is unclear whether etoposide/cisplatin (EP) regimen is the optimal chemotherapy regimen in the treatment patients with extensive small cell lung cancer (SCLC), this study was aimed to evaluate the efficacy and safety of patients with extensive SCLC treated with irinotecan...

Full description

Bibliographic Details
Main Authors:	Nan YAO, Lei JIANG, Kehu YANG, Yancheng YE, Denghai MI, Guangtao MIN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-08-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Irinotecan Etoposide Cisplatin Lung neoplasms Systematic review
Online Access:	http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.08.010&path[]=988

Similar Items

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
by: Thierry Berghmans, et al.
Published: (2017-09-01)

Efficacy and safety of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer
by: LI Nengsheng, et al.
Published: (2019-01-01)

A Randomized Controlled Study of Chemotherapy:  Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment  of Extensive-stage Small Cell Lung Cancer in Elderly Patients
by: Dan PU, et al.
Published: (2013-01-01)

The Effects of Glutathione on Clinically Essential Fertility Parameters in a Bleomycin Etoposide Cisplatin Chemotherapy Model
by: Hale Bayram, et al.
Published: (2023-03-01)

Small Cell Carcinoma of the Tonsil Treated with Irinotecan and Cisplatin: A Case Report and Literature Review
by: Yuichi Segawa, et al.
Published: (2011-12-01)

Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy
by: Du M, et al.
Published: (2022-12-01)

A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage Treatment in Refractory or Relapsed Small Cell Lung Cancer
by: Shufei YU, et al.
Published: (2013-09-01)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
by: Akito Fukuda, et al.
Published: (2022-01-01)

Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study
by: Mangesh P Kamath, et al.
Published: (2016-01-01)

Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
by: Fei Xu, et al.
Published: (2018-08-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Vinorelbine plus Oxaliplatin versus Vinorelbine plus Cisplatin for Advanced Non-small Cell Lung Cancer: A Systematic Review
by: Kehu YANG, et al.
Published: (2010-02-01)

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study
by: Chang Liu, et al.
Published: (2021-04-01)

Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer
by: I Ya Bazaeva, et al.
Published: (2015-09-01)

Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
by: Rodrigo Ramella Munhoz, et al.
Published: (2013-09-01)

Pharmacotherapy of small cell lung cancer: Current state-of-the-art
by: Tatyana A. Berezhnova, et al.
Published: (2023-03-01)

A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus
by: Bahram Mofid, et al.
Published: (2016-10-01)

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
by: Hisashi Tanaka, et al.
Published: (2021-07-01)

Neobavaisoflavone May Modulate the Activity of Topoisomerase Inhibitors towards U-87 MG Cells: An In Vitro Study
by: Mateusz Maszczyk, et al.
Published: (2021-07-01)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012-09-01)

Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension
by: Raid Aljumaily, et al.
Published: (2011-01-01)

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
by: Yelan Guan, et al.
Published: (2023-08-01)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
by: Chunsheng Wu, et al.
Published: (2020-01-01)

Hypersensitivity to Etoposide in Case of Metastatic Gestational Choriocarcinoma
by: Biljana Lazović, et al.
Published: (2013-09-01)

Irinotecan-Induced Dysarthria
by: Albertine J. Dressel, et al.
Published: (2012-01-01)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
by: Longfeng Zhang, et al.
Published: (2020-12-01)

Natural Polyphenols as Modulators of Etoposide Anti-Cancer Activity
by: Magdalena Kluska, et al.
Published: (2021-06-01)

Current Development of Anti-Cancer Drug S-1
by: Pratima Chhetri, et al.
Published: (2016-11-01)

Cisplatin Induced Nephrotoxicity
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2014-02-01)

Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study
by: Rafael Kaliks, et al.
Published: (2010-09-01)

Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study
by: Rafael Kaliks, et al.
Published: (2010-09-01)

Synergistic Effect of Vitamin C with Cisplatin for Inhibiting Proliferation of Gastric Cancer Cells
by: Ghazaleh Ghavami, et al.
Published: (2020-03-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Weekly Paclitaxel and Cisplatin in the Treatment of Elderly Advanced Non-small Cell Lung Cancer
by: Ying LIANG, et al.
Published: (2009-10-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

Thermo-chemotherapy of GP or TP for Advanced Non-small Cell Lung Cancer:  A Systematic Review
by: Denghai MI, et al.
Published: (2012-08-01)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
by: Bei Yue, et al.
Published: (2021-10-01)

Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer
by: Ahmad Ameri (MD), et al.
Published: (2008-10-01)